Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week double-blind study of two doses of teduglutide in pediatric short bowel syndrome patients dependent on parenteral support
2015-002252-27Phase 3Completed
- Sponsor
- NPS Pharmaceuticals, Inc.
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of teduglutide in short bowel syndrome (SBS) (2 arms), sponsored by NPS Pharmaceuticals, Inc. Primary endpoint: Parenteral support volume reduction at 24 weeks. Started Jan 2016; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2015-002252-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002252-27.